<DOC>
	<DOCNO>NCT02588521</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 4 part study ass safety , tolerability , pharmacokinetics antiviral activity orally administer AL-794 healthy volunteer ( HV ) .</brief_summary>
	<brief_title>A Study AL-794 Evaluate Safety , Tolerability , Pharmacokinetics Single Multiple Doses , Antiviral Activity Multiple Doses Influenza Challenge Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Subject provide write consent . 2 . In investigator 's opinion , subject able understand comply protocol requirement , instruction , protocol state restriction likely complete study plan . 3 . Subject good health deem investigator , base finding medical evaluation include medical history , physical examination , laboratory test ECG . 4 . Male female , 1860 year age ( Parts 13 ) . For Part 4 , Males female , 1855 year age . 5 . Body mass index ( BMI ) 1830kg/m2 , inclusive . The minimum weight 50 kg . 6 . A female subject eligible participate study non childbearing potential postmenopausal receive hormone replacement therapy . 7 . If male , subject surgically sterile practice specific form birth control 90 day end study . 1 . Clinically significant cardiovascular , respiratory , renal , gastrointestinal , hepatic , hematologic , neurologic , thyroid medical illness psychiatric disorder , determine Investigator , and/or Sponsor 's Medical Monitor . 2 . Positive screen test hepatitis A , B , C HIV infection . 3 . Clinically significant laboratory abnormality abnormality deem interfere ability interpret study data . 4 . Creatinine clearance le 60 mL/min ( Cockroft Gault ) . 5 . Total bilirubin , ALT , AST , Alkaline Phosphatase &gt; 1.2 X ULN . 6 . Any condition , opinion investigator , would compromise study 's objective wellbeing subject prevent subject meeting study requirement . 7 . Participation investigational drug trial receive investigational vaccine within 3 month prior study medication ( inoculation Part 4 subject ) . 8 . Clinically significant abnormal ECG finding . 9 . Clinically significant blood loss elective blood donation significant volume ( i.e. , &gt; 500 mL ) within 90 day first dose study drug 10 . Heart rate , respiratory rate , temperature blood pressure value outside normal range , per local standard . 11 . Unwilling abstain alcohol 1 week start admission final Completion Visit assessment . 12 . History regular alcohol intake &gt; 14 unit per week alcohol female &gt; 21 unit per week male ( one unit define 8 g alcohol ) within 3 month admission . 13 . For Parts 13 , subject history tobacco use use nicotinecontaining product within 2 week screen visit . For Part 4 , subject significant history tobacco use time . 14 . The subject positive prestudy drug screen . 15 . The use concomitant medication , include prescription , counter medication , herbal medication , inducer inhibitor CYP450 enzymes drug transporter ( include Pgp ) , within 14 day prior first dose study medication , unless approve Sponsor 's Medical Monitor . Occasional use ibuprofen acetaminophen permit . 16 . Exposure four new investigational entity within 12 month prior first dose day ( Parts 13 ) inoculation ( Part 4 ) . 17 . Evidence active infection , include respiratory tract infection within 2 week prior admission . 18 . Pregnant nursing female , woman childbearing potential . Men whose female partner pregnant contemplate pregnancy date screen 90 day end study . 19 . Hypersensitivity active substance excipients AL794 . 20 . Unwillingness inability comply study protocol reason . 21 . Part 4 ONLY : Contraindications challenge influenza virus procedure relate influenza challenge study . For example : Subject serosuitable . Immunocompromised status diagnosis active autoimmune disease . Known allergy constituent challenge virus . History severe illness adulthood due respiratory virus . Inability tolerate repeat nasopharyngeal swab . Abnormal pulmonary function opinion Investigator , evidence response respiratory screening question /or clinically significant abnormality spirometry . Significant history asthma . Any significant abnormality alter anatomy nose nasopharynx . Any clinically significant history epistaxis . Any nasal sinus surgery within six month inoculation . Health care worker reasonably likely come contact severely immunocompromised patient Presence household member close contact know immunodeficiency , receive immunosuppressant medication , undergo soon undergo cancer chemotherapy , diagnose emphysema , COPD , severe lung disease , receive bone marrow solid organ transplant , reside nursing home Evidence vaccination within four week prior inoculation/dosing , whichever occur first . Intention receive vaccination ( ) Day 28 Follow Up Visit Prior participation another Human Viral Challenge Study precede 12 month take date inoculation previous study date expect inoculation study . Receipt systemic glucocorticoid systemic antiviral drug within six month prior inoculation/dosing . Receipt systemic chemotherapy agent , immunoglobulins cytotoxic immunosuppressive drug time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>